No Data
No Data
Longeveron Reports Q2 Results
Buy Rating Reaffirmed for Longeveron on Strong Clinical Trial Prospects and Regulatory Advantages
Longeveron: Cash and Cash Equivalents Expected to Be Sufficient to Fund Co Through 4Q of 2025 >LGVN
Longeveron Q2 2024 GAAP EPS $(1.83) Up From $(2.67) YoY, Sales $468.00K Miss $525.00K Estimate
Earnings Flash (LGVN) LONGEVERON Reports Q2 Revenue $468,000, Vs. Street Est of $0.5M
Longeveron | 10-Q: Q2 2024 Earnings Report
No Data
SeaBird0110 : Haha good luck
Pearls Dad OP SeaBird0110 : Thank you sir! Lol I traded this one before and I’m down like 75 bucks, I’m not worried at all lol I’ll take a 75 dollar loss any day versus hundreds, but I know this is going to make me money, slow and steady wins the race![checkered_flag 🏁](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f3c1.png)
tian liang Pearls Dad OP : Now 2,38
Pearls Dad OP tian liang : 2.34 lol not selling at a loss, I believe in this company!